A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy

Whole exome sequencing can identify somatic mutations in malignant tumors and allow for personalized and novel treatment of common malignancies. Mutations in the BRAF gene are rare in renal cell carcinoma, and thus, BRAF inhibitors are not considered standard in the treatment of these cancers.

Here, we report a case of a patient with a rare BRAF-mutated metastatic renal cell carcinoma who obtained a good clinical response to BRAF inhibition. This case underscores the value of precision medicine in an era of rapidly evolving therapeutics for malignancies.

Curēus. 2016 Jan 06*** epublish ***

Natasha Banerjee, Esha Sachdev, Robert A Figlin

Oncology, Cedars-Sinai Medical Center., Internal Medicine, Cedars-Sinai Medical Center., Oncology, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute.